GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.15% year-on-year.
Overvalued
The company’s latest PE is 1421.24, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 34.23M shares, increasing 2.89% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.18M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.10.